Table 1 Observation schedule

Informed consent

●

Eligibility confirmation

●

●

MMSE

●

Patient background

●

Medical history/complications

●

Decision on dose increase of levodopa-containing medications

●

●

●

●

●

●

●

●

●

CGI-S

●

●

●

●

●

●

●

●

●

●

CGI-I

●

●

●

●

●

●

●

●

●

PGI-S

●

●

●

●

●

●

●

●

●

●

PGI-I

●

●

●

●

●

●

●

●

●

mH&Y (ON/OFF)

●

●

●

●

MDS-UPDRS

(part I, II, III, IV)

●

●

●

●

PDQ-39

●

●

●

●

Wearable device data

●

●

●

●^e

Symptom diary^d

●

●

●

●^e

Hospitalizations

●

●

●

●

●

●

●

●

●

●

●

●

●

Concomitant medication check

●

●

●

●

●

●

●

●

●

●

●

●

●

Adverse events

●

●

●

●

●

●

●

●

●

●

●

●

●

Information on discontinuation

At any time

Data entry into the case report form

Within 2 weeks after each visit